Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic Cancer
Primary Purpose
Status
No longer available
Phase
Locations
Study Type
Expanded Access
Intervention
Pemigatinib
Sponsored by

About this trial
This is an expanded access trial
Eligibility Criteria
Inclusion Criteria:
-
Exclusion Criteria:
-
Sites / Locations
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT03906357
First Posted
April 4, 2019
Last Updated
April 11, 2022
Sponsor
Incyte Corporation
Collaborators
H. Lee Moffitt Cancer Center and Research Institute
1. Study Identification
Unique Protocol Identification Number
NCT03906357
Brief Title
Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic Cancer
Study Type
Expanded Access
2. Study Status
Record Verification Date
April 2022
Overall Recruitment Status
No longer available
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Incyte Corporation
Collaborators
H. Lee Moffitt Cancer Center and Research Institute
4. Oversight
5. Study Description
Brief Summary
Expanded access of Pemigatinib to treat a single patient with metastatic pancreatic cancer.
6. Conditions and Keywords
7. Study Design
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Pemigatinib
Other Intervention Name(s)
INCB054828
10. Eligibility
Eligibility Criteria
Inclusion Criteria:
-
Exclusion Criteria:
-
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dae Won Kim, MD
Organizational Affiliation
H. Lee Moffitt Cancer Center and Research Institute
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic Cancer
We'll reach out to this number within 24 hrs